PALSONIFY Shows Durable Acromegaly Control for Two Years in New Clinical Data
CRNX sits 33% above its 52-week low of $25.83.
Summary
Crinetics Pharmaceuticals presented positive long-term data for its key drug PALSONIFY (paltusotine) at ENDO 2026. The data from open-label extension studies showed durable and consistent control of acromegaly for up to two years, maintaining lower IGF-1 levels and stable symptoms, with stable or reduced pituitary tumor volumes for up to 48 weeks. This follows the company's pre-announcement of the presentation on June 3rd and builds on the European Commission approval in April and strong Q1 product revenue for PALSONIFY. This long-term efficacy and safety data is crucial for physician adoption and strengthens the drug's commercial potential in the chronic acromegaly market.
At the time of this announcement, CRNX was trading at $34.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.6B. The 52-week trading range was $25.83 to $57.99. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.